Dupilumab, a monoclonal antibody targeting the IL4Rα subunit, has shown efficacy in mitigating type 2 inflammatory diseases, including asthma and CRSwNP. This evidence concerns the gene IL4R and chronic rhinosinusitis with nasal polyps.